You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

10 Results
Drug
Other Name(s): Tomudex®
Sep 2024
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Funding:
New Drug Funding Program
    Gemcitabine and Nab-Paclitaxel - Advanced Pancreatic Cancer
Jan 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Jan 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Small bowel and appendix
Intent: Adjuvant, Palliative
Funding:
New Drug Funding Program
    Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer
New Drug Funding Program
    Raltitrexed - Adjuvant Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Raltitrexed - Adjuvant Esophageal, Gastroesophageal Junction, or Gastric Cancer
Jun 2024
Guidelines and Advice
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Jan 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Glofitamab (Outpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma
High Cost Therapy Funding Program
    Glofitamab (Inpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sep 2024
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Dec 2024